Laboratory Monitoring of Patients Treated with Antihypertensive Drugs and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs: A Cohort Study

Jean-Pascal Fournier1,2,3*, Maryse Lapeyre-Mestre1,2,4, Agnès Sommet1,2,4, Julie Dupouy1,2,3, Jean-Christophe Poutrain3, Jean-Louis Montastruc1,2,4

1 Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université Paul Sabatier, Toulouse, France, 2 UMR1027, Inserm, Toulouse, France, 3Département Universitaire de Médecine Générale, Faculté de Médecine, Université Paul Sabatier, Toulouse, France, 4Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacépidémiologie et d’Information sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

**Abstract**

**Background:** Drug-Drug Interactions between Non Steroidal Anti-Inflammatory Drugs (NSAIDs) and Angiotensin Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blocker (ARBs) or diuretics can lead to renal failure and hyperkalemia. Thus, monitoring of serum creatinine and potassium is recommended when a first dispensing of NSAID occur in patients treated with these drugs.

**Methods:** We conducted a pharmacoepidemiological retrospective cohort study using data from the French Health Insurance Reimbursement Database to evaluate the proportion of serum creatinine and potassium laboratory monitoring in patients treated with ACEI, ARB or diuretic and receiving a first dispensing of NSAID. We described the first dispensing of NSAID among 3,500 patients of a 4-year cohort (6,633 patients treated with antihypertensive drugs) and analyzed serum creatinine and potassium laboratory monitoring within the 3 weeks after the first NSAID dispensing.

**Results:** General Practitioners were the most frequent prescribers of NSAIDs (85.5%, 95% CI: 84.3–86.6). The more commonly prescribed NSAIDs were ibuprofen (20%), ketoprofen (15%), diclofenac (15%) and piroxicam (12%). Serum creatinine and potassium monitoring was 10.7% (95% CI: 9.5–11.8) in patients treated by ACEIs, ARBs or diuretics. Overall, monitoring was more frequently performed to women aged over 60, treated with digoxin or glucose lowering drugs, but not to patients treated with ACEIs, ARBs or diuretics. Monitoring was more frequent when NSAIDs’ prescribers were cardiologists or anesthesiologists.

**Conclusion:** Monitoring of serum creatinine and potassium of patients treated with ACEIs, ARBs or diuretics and receiving a first NSAID dispensing is insufficiently performed and needs to be reinforced through specific interventions.

---

**Introduction**

Because Non Steroidal Anti-Inflammatory Drugs (NSAIDs) inhibit cyclooxygenase enzymes (COX) and prevent prostaglandin synthesis, their drug-drug interactions (DDIs) with antihypertensive drugs can lead to adverse drug reactions [1]. NSAIDs association with these drugs can increase arterial blood pressure. Concomitant use of NSAIDs with Angiotensin Conversion Enzyme inhibitors (ACEIs), Angiotensin Receptors Blockers (ARBs) or diuretics can also precipitate acute renal failure, hyponatremia or hyperkalemia, especially when used on elderly or dehydrated individuals. Moreover, the risk of significant renal impairment is associated with the number of these drugs, when they are associated [2].

In France, two drug interaction compendia are available. The main one is provided by the Agence Française de Sécurité Sanitaire et des Produits de Santé (Afssaps, the French Drug Agency) and is available online [3]. The concise information provided in this guideline is used by the main drug databases (especially the French National Formulary: *Vidal* [4]). The second one is the annual supplement of the French independent drug information bulletin *La Revue Pratique* [5]. Recommendations are to monitor serum creatinine alone [4], and even serum creatinine and potassium [5] whenever NSAIDs are first prescribed with ACEIs, ARBs or diuretics (Table S1). However, prescribers’ compliance to these recommendations had not been fully evaluated. Thus, we performed a pharmacoepidemiological cohort study investigating if these laboratory monitoring are currently followed by practitioners.

**Methods**

All the French population is covered by a publicly funded health system. The French Health Insurance Reimbursement Database gathers information concerning these patients. Four kinds of data...
are computerized in this database: demographic characteristics of users, characteristics of health professionals, data concerning health facilities and reimbursement data (drug, laboratory, radiology, medical acts) [6]. Concerning drug dispensing, the database contains information on the date of dispensing, quantity dispensed, and prescriber. Drugs are classified according to the Anatomical Therapeutic Chemical system [7].

**Study population**

We extracted a random sample of patients (sample rate: 5%, as provided by the French Health Insurance System Database), living in the Midi-Pyrénées area (2,600,000 inhabitants) between 1 April 2005 and 1 April 2006, receiving at least two prescriptions of the same antihypertensive drug and not receiving any NSAID (including topical, injectable and oral forms) during this period. Inclusion in the study was on 1 April 2006 for all patients and the maximal follow-up was 4 years (until 31 March 2010, because of database size limitations). Patients were considered lost-to-follow-up if having no drug dispensing for more than 3 months. All data were anonymous in conformity with the French Law of Privacy (8).

The following oral and injectable NSAIDs marketed in France during the period of study were extracted: arylcarboxylic acids (aceclofenac, alminoprofen, diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen, nabumetone, tiaprofenic acid), oxicas (meloxicam, piroxicam, tenoxicam), coxibs (celecoxib), acetylsalicylic acid (excluding anti-platelet doses) and others (indometacin, sulindac, phenylbutazone, nimesulide, mefenamic acid, mornilumate, niflumic acid).

Antihypertensive drugs included beta-blocking agents, ACEIs, ARBs, diuretics (except eplerenone), calcium channel blockers (except bepridil), alpha-blocking agents or other drugs (centrally acting antihypertensive drugs, minoxidil and dihydralazine). Renin inhibitors were not available in France during the period of study and thus were not included in the analysis. We took into account fixed combinations of antihypertensive drugs as separate drugs.

The level of renal failure and hyperkalemia risk caused by NSAID/antihypertensive DDIs was graduated in risk levels, as was the risk of heart failure. Comorbid conditions with laboratory monitoring in univariate analysis (p < 0.2) were assessed using logistic regression modeling. Characteristics considered in univariate models included age, gender, level of renal failure and hyperkalemia risk caused by DDIs with antihypertensive drugs, digoxin, potassium supplements, glucose lowering drugs, platelet anti-aggregating agents, hospitalizations in the three months previous first dispensing of NSAIDs. Statistical analyses were performed using Stata®, version 11.0 (StataCorp LP, College Station, TX).

**Results**

**Cohort**

Over the 6,633 patients of the cohort, 3,622 had a first dispensing of NSAIDs during the follow-up (incidence rate: 25.1/100 PY). Among them, 122 were not treated with antihypertensive drug anymore when the first dispensing of NSAID occurred and were thus excluded from the analysis (figure 1). Among the 3,500 remaining patients, 22 had a first dispensing of two different NSAIDs, always prescribed by the same physician. The characteristics of the first dispensing of NSAIDs are shown in table 2. Overall, 2,696 (77.0%) patients were classified at risk of DDI («one drug»: 41.6%, «two drugs»: 35.3%). General Practitioners (GPs) prescribed the majority of NSAIDs (85.5%, 95% CI: 84.3–86.6), and mainly ibuprofen (18.6%), diclofenac (16.3%), ketoprofen (15.4%) or piroxicam (13.4%). Dentists preferentially prescribed ibuprofen (52.2%) and surgeons mainly prescribed ketoprofen (15.2%). Cardiologists and anesthetists mainly prescribed flurbiprofen (76.9% and 90.5% of their NSAIDs prescriptions).

**Serum creatinine and potassium monitoring**

Baseline complete monitoring was performed in 59.1% (95% CI: 57.3–61.0) of patients treated by ACEIs, ARBs or diuretics (“at risk” group). In only 10.7% (95% CI: 9.5–11.8) of these patients, a complete laboratory monitoring was recorded in the three weeks after NSAID initiation. This monitoring occurred by mean on the 8th day (8.5±6.1) after the first dispensing of NSAID. Table 3 shows the different rates of monitoring according to DDI risks.

Univariate analysis showed that all the characteristics selected were associated to serum creatinine and potassium monitoring (table 4). Multivariate analysis performed with these variables (table 5), showed that being aged over 60 (60–70: OR = 1.78, 95% CI: 1.00–3.15; 70–80: OR = 2.17, 95% CI: 1.26–3.73; over 80: OR = 3.14, 95% CI: 1.79–5.48) and a woman (OR = 1.26, 95% CI: 1.00–1.59) was associated with a more frequent monitoring. Monitoring was also more frequent among patients treated with potassium supplements (OR = 2.47, 95% CI: 1.49–4.12) and glucose lowering drugs (OR = 1.58, 95% CI: 1.22–2.06) but not in patients treated with ACEI, ARBs or diuretics («one drug» OR = 1.27, 95% CI: 0.92–1.75; «two drugs» OR = 1.28, 95% CI:

**Table 1. Risk of renal failure/hyperkalemia caused by DDIs with NSAIDs according to classes of antihypertensive drugs.**

| Risk group | Antihypertensive classes |
|------------|-------------------------|
| No risk    | Beta-blocking agents    |
|            | Calcium channel blockers|
|            | Alpha-Blocking agents   |
|            | Other antihypertensives  |
| At risk of DDI* | Diuretics or ACEI or ARB |
| «one drug» | Diuretics + ACEI/ARB     |
| «two drugs and more» | Diuretics + ACEI/ARB   |

**Table 2.**

| Characteristics | «one drug» | «two drugs» |
|----------------|-----------|------------|
| Age (y)        | 25.1      | 25.4       |
| Gender (%)     | 53.4      | 46.6       |
| Renal failure  | 15.4%     | 16.4%      |
| Hyperkalemia   | 15.4%     | 16.4%      |
| Diabetes (%)   | 24.2%     | 25.6%      |
| Heart failure  | 5.1%      | 5.3%       |

**Table 3.**

| Monitoring | «one drug» | «two drugs» |
|-----------|-----------|------------|
| 8th day (8.5±6.1) | 59.1% | 59.3% |
| 6th day (6.1±5.3) | 56.8% | 57.0% |
| 4th day (4.1±4.2) | 54.6% | 54.8% |
| 2nd day (2.1±2.2) | 52.4% | 52.6% |

**Table 4.**

| Characteristics | «one drug» | «two drugs» |
|----------------|-----------|------------|
| Age (y)        | 25.1      | 25.4       |
| Gender (%)     | 53.4      | 46.6       |
| Renal failure  | 15.4%     | 16.4%      |
| Hyperkalemia   | 15.4%     | 16.4%      |
| Diabetes (%)   | 24.2%     | 25.6%      |
| Heart failure  | 5.1%      | 5.3%       |

**Table 5.**

| Characteristics | «one drug» | «two drugs» |
|----------------|-----------|------------|
| Age (y)        | 25.1      | 25.4       |
| Gender (%)     | 53.4      | 46.6       |
| Renal failure  | 15.4%     | 16.4%      |
| Hyperkalemia   | 15.4%     | 16.4%      |
| Diabetes (%)   | 24.2%     | 25.6%      |
| Heart failure  | 5.1%      | 5.3%       |

**Figure 1.**

Baseline complete monitoring was performed in 59.1% (95% CI: 57.3–61.0) of patients treated by ACEIs, ARBs or diuretics (“at risk” group). In only 10.7% (95% CI: 9.5–11.8) of these patients, a complete laboratory monitoring was recorded in the three weeks after NSAID initiation. This monitoring occurred by mean on the 8th day (8.5±6.1) after the first dispensing of NSAID. Table 3 shows the different rates of monitoring according to DDI risks.

Univariate analysis showed that all the characteristics selected were associated to serum creatinine and potassium monitoring (table 4). Multivariate analysis performed with these variables (table 5), showed that being aged over 60 (60–70: OR = 1.78, 95% CI: 1.00–3.15; 70–80: OR = 2.17, 95% CI: 1.26–3.73; over 80: OR = 3.14, 95% CI: 1.79–5.48) and a woman (OR = 1.26, 95% CI: 1.00–1.59) was associated with a more frequent monitoring. Monitoring was also more frequent among patients treated with potassium supplements (OR = 2.47, 95% CI: 1.49–4.12) and glucose lowering drugs (OR = 1.58, 95% CI: 1.22–2.06) but not in patients treated with ACEI, ARBs or diuretics («one drug» OR = 1.27, 95% CI: 0.92–1.75; «two drugs» OR = 1.28, 95% CI:...
Figure 1. Selection of the 3,500 antihypertensive-treated patients with a first dispensing of NSAIDS. doi:10.1371/journal.pone.0034187.g001

Table 2. Characteristics of the first dispensing of NSAID.

| Characteristics | NSAID (all) | Ibuprofen | Ketoprofen | Diclofenac | Piroxicam | Celecoxib | Acetylsalicylic Acid |
|-----------------|-------------|-----------|------------|------------|-----------|-----------|---------------------|
| Number of patients, n (%) | 3,500 (100.0) | 722 (20.6) | 531 (15.2) | 526 (15.0) | 416 (11.9) | 124 (3.5) | 144 (4.1) |
| DDD dispensed, n (m ± sd) | 13.5 ± 7.8 | 7.5 ± 3.9 | 18.4 ± 8.1 | 17.3 ± 6.2 | 13.8 ± 5.2 | 28.1 ± 6.9 | 5.8 ± 3.0 |
| Time since index date, d (med [IQR]) | 376 [170–718] | 418 [208–786] | 404 [174–828] | 444 [194–787] | 258 [126–480] | 476 [176–833] | 321 [169–622] |
| Prescriber, n (%) | | | | | | | |
| General Practitioner | 2,992 (85.5) | 560 (77.6) | 464 (87.4) | 492 (93.5) | 403 (96.9) | 116 (93.5) | 139 (96.5) |
| Dentist | 274 (7.8) | 143 (19.8) | 12 (2.3) | 4 (0.8) | 1 (0.2) | 0 (0.0) | 1 (0.7) |
| Other prescribers | 230 (6.6) | 18 (2.5) | 55 (10.3) | 30 (5.7) | 12 (2.9) | 8 (6.4) | 4 (2.8) |
| Surgeons | 76 (2.2) | 11 (1.5) | 31 (5.8) | 13 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Rheumatologist | 57 (1.6) | 2 (0.3) | 12 (2.3) | 9 (1.7) | 6 (1.4) | 6 (4.8) | 1 (0.7) |
| Anesthesiologist | 21 (0.6) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cardiologist | 13 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.4) |
| Other | 67 (1.9) | 5 (0.7) | 10 (1.9) | 8 (1.5) | 6 (1.4) | 0 (0.0) | 0 (0.0) |
| Missing | 4 (0.1) | 1 (0.1) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (1.6) | 1 (0.7) |

| Antihypertensive drug DDI risk, n (%) | | | | | | | |
| No risk | 804 (23.0) | 168 (23.3) | 122 (23.0) | 115 (21.9) | 95 (22.8) | 24 (19.3) | 33 (22.9) |
| At risk of DDI² | 2,696 (77.0) | 554 (76.7) | 409 (77.0) | 411 (78.1) | 321 (77.2) | 100 (80.6) | 111 (77.1) |
| «one drug» | 1,460 (41.7) | 289 (40.0) | 219 (41.2) | 214 (40.7) | 190 (45.7) | 57 (46.0) | 59 (39.6) |
| «two drugs and more » | 1,236 (35.3) | 265 (36.7) | 190 (35.8) | 197 (37.4) | 131 (31.5) | 43 (34.7) | 54 (37.5) |

n, number; m, mean; sd, standard deviation; d, days; med, median; IQR, interquartile range; DDI Drug-Drug interaction.
NSAIDs, non steroidal anti-inflammatory drugs; DDD, defined Daily Dose; Acetylsalicylic Acid: excluding anti-platelet dose.
²At risk of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs) between NSAIDs and antihypertensives (see table 1).
doi:10.1371/journal.pone.0034187.t002
Discussion

Our study was performed to evaluate the implementation of laboratory monitoring in patients treated with ACEI/ARB/Diuretic plus NSAID. Our results show that despite well-known potential biochemical disturbances, serum creatinine and potassium monitoring were recorded in less than 11% of patients at risk. Monitoring occurred at day 8 and was more frequently performed to women aged over 60, treated with potassium supplements or glucose lowering drugs, but not to patients treated with ACEI, ARBs or diuretics. Monitoring was more frequent when NSAIDs’ prescriber was a cardiologist or anesthesiologist.

The characteristics of NSAID prescriptions are close to the ones found in a monthly prevalence descriptive study leaded in the same area in 2006 [9]. First prescriptions of NSAIDs among hypertensive patients do not differ from NSAIDs prescriptions in general population, as the more frequently prescribed NSAIDs are in both studies ibuprofen, ketoprofen, diclofenac and piroxicam. Our study adds information on specificities of NSAIDs’ prescriptions among prescribers. Among GPs, the rate of piroxicam prescriptions remains high, but is decreasing compared to previous studies performed in the same area [10]. This phenomenon may reflect the recent recommendation from the Haute Autorité de Santé (equivalent of the National Institute for Health and Clinical Excellence in France), underlining that piroxicam remains a second-line NSAID [11] in its main indications. We also found that dentists’ prescriptions were preferentially ibuprofen, the NSAID commonly prescribed for its anti-inflammatory and analgesic effect in acute dental pain [12].

To our knowledge, this study is the first one describing monitoring of serum creatinine and potassium in patients at risk of renal failure or hyperkalemia caused by NSAID DDIs with ACEI, ARBs or diuretics. The rate found in our study (around 11%) is unsurprisingly low. Low monitoring rates have been found in previous study whether in RASIs initiation (34% of control in the first 3 weeks [8]) or with chronically prescribed ARBs/ACEIs/diuretics (68 to 72% of annual control [14]). Furthermore, in our study the level of DDIs risk is not associated with a greater control. In Bootsma et al. study [8], being under NSAIDs was not associated to an adequate control either in patients starting ACEI/ARB therapy.

Table 3. Serum creatinine and potassium monitoring before* and after start of NSAID.†

| Risk group, n | Laboratory monitoring before start of NSAID* [n (%)] | Laboratory monitoring after start of NSAID † [n (%)] |
|--------------|---------------------------------------------------|--------------------------------------------------|
|              | Creatinine and potassium monitoring | Creatinine monitoring | Potassium monitoring | Creatinine and potassium monitoring | Creatinine monitoring | Potassium monitoring |
|              | (n = 1,942) | (n = 534) | (n = 374) | (n = 347) | (n = 532) | (n = 372) |
| No risk, 804 | 348 (43.3) | 511 (63.6) | 367 (45.6) | 59 (7.3) | 109 (13.6) | 66 (8.2) |
| At risk of DDI, 2,696 |                     |                             |                          |                          |                          |                          |
| <one drug>, 1,460 | 833 (57.0) | 1,038 (71.1) | 870 (59.6) | 154 (10.5) | 225 (15.4) | 164 (11.2) |
| <two drugs and more>, 1,236 | 761 (61.6) | 880 (71.2) | 792 (64.1) | 134 (10.8) | 198 (16.0) | 142 (11.5) |

NSAIDs, non steroidal anti-inflammatory drugs.

*In the year previous first NSAID dispensing.
†In the 3 weeks after start of NSAID.
‡At risk of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs) between NSAIDs and antihypertensives (see table 1).

Table 4. Serum creatinine and potassium monitoring after start of NSAID according to NSAID prescriber.

| NSAID Prescriber (n) | Laboratory monitoring after start of NSAID* [n (%)] |
|----------------------|---------------------------------------------------|
|                      | Creatinine and potassium monitoring | Creatinine monitoring | Potassium monitoring |
|                      | (n = 347) | (n = 532) | (n = 372) |
| General Practitioner (2,992) | 294 (9.8) | 459 (15.3) | 317 (10.6) |
| Dentist (274) | 24 (8.8) | 35 (12.8) | 24 (8.8) |
| Other prescribers (238) | 29 (12.2) | 38 (16.0) | 31 (13.0) |
| Anesthesiologist (21) | 4 (19.0) | 7 (33.3) | 5 (23.8) |
| Cardiologist (13) | 5 (38.5) | 5 (38.5) | 5 (38.5) |
| Surgeons (76) | 9 (11.8) | 14 (18.4) | 9 (11.8) |
| Rheumatologist (56) | 3 (5.4) | 4 (7.1) | 3 (5.4) |
| Other (67) | 8 (12.5) | 8 (12.5) | 9 (14.1) |

NSAIDs, non steroidal anti-inflammatory drugs.

doi:10.1371/journal.pone.0034187.t003
doi:10.1371/journal.pone.0034187.t004
Table 5. Factors associated with serum creatinine and potassium after start of NSAID.

| Factors                              | Unadjusted odds ratio | p       | Adjusted odds ratio  | p     |
|--------------------------------------|-----------------------|---------|----------------------|-------|
| Age, years (<50 years as reference)  |                       |         |                      |       |
| 50–60                                | 1.70 [0.94–3.07]       | 0.075   | 1.64 [0.91–2.95]     | 0.147 |
| 60–70                                | 1.89 [1.07–3.34]       | 0.028   | 1.78 [1.00–3.15]     | 0.049 |
| 70–80                                | 2.51 [1.44–4.36]       | 0.001   | 2.31 [1.32–4.04]     | 0.003 |
| >80                                  | 3.42 [1.94–6.03]       | 0.000   | 3.36 [1.90–5.96]     | 0.000 |
| Gender (male as reference)           |                       |         |                      |       |
|                                      | 1.18 [0.95–1.48]       | 0.129   | 1.26 [1.00–1.59]     | 0.044 |
| Concomitant drugs†                   |                       |         |                      |       |
| Potassium supplements                | 2.88 [1.74–4.75]       | 0.000   | 2.47 [1.49–4.12]     | 0.001 |
| Glucose lowering drugs               | 1.58 [1.22–2.04]       | 0.001   | 1.58 [1.22–2.06]     | 0.001 |
| Digoxin                              | 2.04 [1.17–3.54]       | 0.012   | 1.60 [0.91–2.82]     | 0.106 |
| Platelet aggregation inhibitors      | 1.49 [1.17–1.88]       | 0.001   | 1.20 [0.93–1.54]     | 0.153 |
| Risk level of DDI† (no risk as reference) |                       |         |                      |       |
| One drug                             | 1.49 [1.09–2.04]       | 0.013   | 1.27 [0.92–1.75]     | 0.139 |
| Two drugs                            | 1.53 [1.11–2.11]       | 0.009   | 1.28 [0.92–1.77]     | 0.140 |
| Hospitalizations‡ (any)              | 2.68 [1.14–6.27]       | 0.023   | 2.09 [0.87–5.00]     | 0.097 |
| NSAID prescriber                     |                       |         |                      |       |
| Cardiologist or Anesthesiologist     | 3.33 [1.54–7.19]       | 0.002   | 3.32 [1.53–7.26]     | 0.003 |

*Adjusted for age, gender, exposure to potassium supplements, glucose lowering drugs and NSAID prescriber.
†According to ATC classification.
‡Risk level of renal failure/hyperkalemia caused by Drug-Drug Interactions (DDIs) between NSAIDs and antihypertensives (see table 1).
§in the 6 months before inclusion.
*Compared to other prescribers.

doi:10.1371/journal.pone.0034187.t005

This study underlines the important lack of implementation of guidelines for DDIs between NSAIDs and antihypertensives. This finding is quite ambiguous, as GP have previously reported their concerns about NSAIDs safety of use in daily practice and claimed a caution approach in NSAID prescription [15]. As an explanation to this phenomenon, two approaches can be considered focusing on guideline-related factors and GPs-related factors [16]. Concerning the quality of the interaction compendia, one should underline that the main one, provided by the French Drug Agency, is available online [3]. The concise information provided in this guideline is used by the main drug databases (especially the French National Formulary: Vidal® [4]) and thus in the main medical software, which automated prompts and alerts have already demonstrated positive effects on decreasing preventable adverse drug events [17]. The main limitation of the recommendations could be the absence of explicit time frame in which the monitoring should be performed. The impact of this lack of precision remains uncertain. Moreover, the recommendations are different in other compendia. Surprisingly, the British National Formulary emphasizes on the increased risk of nephrotoxicity of the association between NSAIDs and ACEIs/ARBs/diuretics, [18] but does not provide recommendations of laboratory monitoring. This lack of consistency between drug interaction compendia has already been raised [19] and underlines the necessity for their standardization.

Regarding GPs-related factors for the non-implementation of drug prescribing guidelines, GPs may consider guidelines as too stringently in general. They consider laboratory monitoring as time-consuming, especially when they are uncertain that monitoring was already performed by another provider [20]. GPs also raise concerns about the real impact of computerized clinical decision support to increase implementation of guidelines, as a phenomenon of alert fatigue could occur. Weingart et al. [21] recently emphasized on the necessity for computerized alerts to be adapted to clinicians.

In the present study, cardiologists and anesthesiologists prescribed more frequently adequate monitoring. This phenomenon can be explained by an increased prescription of flurbiprofen within these two medical specialties. Flurbiprofen is marketed in France for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction, in patients for whom aspirin is not recommended [22]. Thus, these patients could have more frequent monitoring because of their condition. Another explanation could be that these medical specialties are more aware of the risk evaluated in the present study.

Limitations

The use of the French Health Insurance Reimbursement Database in pharmacoepidemiological studies has already been fully described [6], but it implies some limitations. As for many administrative databases, we did not have access to medical characteristics of the patients. This involves using medications as proxies of morbidities (e.g. glucose lowering drugs for diabetes mellitus [23]). We were not able to extract some characteristics associated to serum creatinine and potassium monitoring in a previous study [24], because of database limitations. In this study of Raebel et al., increasing number of outpatient visits and diagnoses of chronic heart failure or kidney disease were associated to annual monitoring. Furthermore, the disease necessitating NSAID prescription could alone be a condition implying a monitoring of serum creatinine and potassium (e.g. renal colic...
Moreover, the database only records monitoring that have been performed and not all the ones that have been prescribed. A lot of patients-related situations (reluctance to blood test, doctor shopping, excessive self-confidence towards adverse drug reactions...) could have an impact on the realization of monitoring in a reasonable time frame.

Finally, the low prevalence of complete monitoring could have been underestimated. In our study, we only have access to ambulatory biochemical monitoring and thus could have missed the ones realized during hospitalizations. On the other hand, one could have underestimated the prevalence of ibuprofen and aspirin consumption, as these specific NSAIDs can be sold out-of-the-counter and thus not recorded in the French Health Insurance Reimbursement Database.

Conclusion
The low prevalence of serum creatinine and potassium monitoring shows a very poor implementation of guidelines. Further studies are required to correlate this low prevalence with a potential increased risk of severe adverse drug reactions. Moreover, intervention studies are required to improve the knowledge of this specific risk, especially among GPs.

Supporting Information
Table S1 Drug interactions between NSAIDs and anti-hypertensive drugs according to the Agence Francaise de Sécurité Sanitaire et des Produits de Santé (= French Drug Agency) and La Revue Prescrire. † There are four levels of seriousness, based on the clinical management which is recommended: ‘contraindication’ (absolute), ‘avoid’ (relative contraindication), ‘precaution for use’ (combination possible if recommendations are followed), and ‘to take into account’ (no specific recommendation) * Afssaps: Agence Francaise de Sécurité Sanitaire et des Produits de Santé (= French Drug Agency).

Acknowledgments
The authors thank Dr Robert Bourrel and Carole Suarez of the Health Insurance System of Midi-Pyrénées for their kind help during the data extraction.

Author Contributions
Conceived and designed the experiments: JPF MLM AS JLM. Performed the experiments: JPF MLM AS JLM. Analyzed the data: JPF MLM AS JLM. Wrote the paper: JPF MLM AS JD JCP JLM.

References
1. Olyaei AJ, Whelton A, Sturmer T, Porter GA (2008) Non-steroidal anti-inflammatory drugs. In: Clinical Nephrotoxins: Renal injury from drugs and chemicals, 3rd ed de Broe ME, Porter GA, eds. pp 419–457.
2. Loboz KK, Shenfield GM (2005) Drug combinations and impaired renal function – the “triple whammy.” Br J Clin Pharmacol 59: 239–243.
3. Saint-Sali B, Huerer S, De Roo P (2009) Thesaurus des interactions médicamenteuses. Available: http://www.afssaps.fr/Documents-therapeutiques/Interactions-medicamenteuses/Interactions-medicamenteuses/%25BFets%29/0. Accessed 15 Dec 2011.
4. Vidal (2011) Vidal 2011: Le Dictionnaire. 87th ed. Paris: O.V.P. eds.
5. Revue Prescrire (2009) Eviter les effets indésirables par interactions médicamenteuses - Le Guide Prescrire Édition 2010. Rev Prescrire 29: 50–63.
6. Martin-Latty K, Bégaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19: 256–265.
7. WHO Collaborating Centre for Drug Statistics Methodology (i.d) ATC/DDD Index. Available: http://www.whocc.no/atc_ddd_index/. Accessed 2011 Dec 15.
8. Bootosa JEM, Warlé-van Horwaarden MF, Verbeek ALM, Fisunenich P, De Smet PAGM, et al. (2011) Adherence to biochemical monitoring recommendations in patients starting with Renin Angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf 34: 605–614.
9. Lugardon S, Roussel H, Boursell R, Scirinti V, Monastrel J-L, et al. (2006) Patterns of non steroidal anti-inflammatory drug use in ambulatory care. Therapie 61: 109–114.
10. Cimaz F, Sgro C, Bardou M, Dumas M, Hilton P, et al. (2001) Non-steroidal anti-inflammatory drug prescribing patterns in general practice: comparison of a general practitioner-based survey and a pharmacy-based survey in France. Pharmacoepidemiol Drug Saf 10: 329–338.
11. Haute Autorité de Santé (2009) Bexin, cycloflo, feldene, prazolox (piroxicam), anti-inflammatoire non stéroidien. Available: http://www.has-sante.fr/portail/jcms/c_834675/bexin-cycloflo-feldene-prazolox-anti-inflammatoire-non-stereoidien. Accessed 2011 Dec 15.
12. Hargraves R, Abbot PV (2005) Drugs for pain management in dentistry. Aust Dent J 50: S14–S22.
13. McGregor P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098.
14. McDowell SE, Fener R (2011) Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review. Drug Saf 34: 1049–1059.
15. Mikhail SS, Zwar NA, Vaghoklar S, Dennis SM, Day RO (2007) Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. Med J Aust 187: 160–163.
16. Langley G, Faulkner A, Watkins C, Gray S, Harvey I (1998) Use of guidelines in primary care–practitioners’ perspectives. Fam Pract 15: 105–111.
17. Schoelbauer A, Prasad V, Mutfacney C, Phamalka S, Stanton W, et al. (2009) What Evidence Supports the Use of Computerized Alerts and Prompts to Improve Clinicians’ Prescribing Behavior? J Am Med Inform Assoc 16: 531–536.
18. British Medical Association, Royal Pharmaceutical Society of Great Britain (2011) British National Formulary 62. London.
19. Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63: 709–714.
20. Goldman RE, Soran CS, Hayward GL, Simon SR (2010) Doctors’ perceptions of laboratory monitoring in office practice. J Eval Clin Pract 16: 1136–1141.
21. Weingart SN, Seger AC, Foola N, Helfman J, Schiff G, et al. (2011) Electronic drug interaction alerts in ambulatory care: the value and acceptability of high-value alerts in US medical practices as assessed by an expert clinical panel. Drug Saf 34: 587–593.
22. Brocher ML (1995) Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 14: 951–957.
23. Brefle-Courbon C, Grobeau S, Thalamas C, Boursell R, Allaria-Lapierre V, et al. (2009) Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 141: 14–18.
24. Rachel MA, McChure DL, Simon SR, Chan KA, Feldstein A, et al. (2007) Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 16: 53–64.
25. Holdgate A, Pollock T (2004) Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ 328: 1401–1401.